Seelos Said Due To The Limited Sample Size, The SLS-002 Study Did Not Meet The Pre-defined Primary Endpoint
Portfolio Pulse from Charles Gross
Seelos Therapeutics announced that its SLS-002 study did not meet the pre-defined primary endpoint due to the limited sample size.
September 20, 2023 | 11:29 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Seelos Therapeutics' SLS-002 study did not meet its primary endpoint, which could negatively impact the company's stock price in the short term.
Clinical trial results are a significant driver of biotech stock prices. The failure of Seelos' SLS-002 study to meet its primary endpoint could be seen as a setback, potentially leading to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100